Analysis Suggests Cost-Effectiveness of Ranibizumab Biosimilar for nAMD Treatment

An analysis based in Japan suggests ranibizumab biosimilar is dominant to other anti-VEGF treatments in patients with nAMD in both treat-and-extend and PRN regimens.

Related Keywords

Yokohama ,Kanagawa ,Japan ,Japanese ,Researchgate Yasuo Yanagi ,Yasuo Yanagi ,Yokohama City University , ,Yokohama City ,